Cargando…

Safety profile of intravenous digoxin in Chinese patients with acute heart failure with reduced ejection fraction: a small-scale prospective cohort study

Background: Adverse effects of intravenous digoxin vary from patients and disease status, which should be closely monitored. Aims: To explore the safety profile of intravenous digoxin in acute heart failure with reduced ejection fraction (HFrEF) among Chinese patients. Methods: A clinical prospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xintian, Zhang, Haojie, Cheng, Wenlin, Fan, Qingkun, Lu, Zhibing, Zheng, Xuan, Zhang, Gangcheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679729/ https://www.ncbi.nlm.nih.gov/pubmed/38026938 http://dx.doi.org/10.3389/fphar.2023.1291896

Ejemplares similares

Effects of Digoxin in Heart Failure (HF) With Reduced Ejection Fraction (EF)
por: Parikh, Riya R, et al.
Publicado: (2022)

Digoxin is associated with worse outcomes in patients with heart failure with reduced ejection fraction
por: Zhou, Jingmin, et al.
Publicado: (2020)

Interaction between Chinese medicine and digoxin: Clinical and research update
por: Zhuang, Wei, et al.
Publicado: (2023)

Traditional Chinese medicine for heart failure with preserved ejection fraction: clinical evidence and potential mechanisms
por: Fan, Yujian, et al.
Publicado: (2023)

Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry
por: Kapelios, Chris J, et al.
Publicado: (2021)

Impact of Digoxin Use on Guideline-Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction
por: Jabri, Ahmad, et al.
Publicado: (2022)

Corrigendum to: Digoxin use in contemporary heart failure with reduced ejection fraction: An analysis from the Swedish Heart Failure Registry
Publicado: (2023)

Efficacy and Safety of Traditional Chinese Medicine Injections for Heart Failure With Reduced Ejection Fraction: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
por: Lin, Shanshan, et al.
Publicado: (2021)

Resveratrol Ameliorates Cardiac Remodeling in a Murine Model of Heart Failure With Preserved Ejection Fraction
por: Zhang, Liyun, et al.
Publicado: (2021)

Efficacy and Safety of Qishen Yiqi Dripping Pill for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
por: Wang, Mengxi, et al.
Publicado: (2021)

Corrigendum: Resveratrol Ameliorates Cardiac Remodeling in a Murine Model of Heart Failure With Preserved Ejection Fraction
por: Zhang, Liyun, et al.
Publicado: (2022)

Pharmacological Tuning of Adenosine Signal Nuances Underlying Heart Failure With Preserved Ejection Fraction
por: Campos-Martins, Alexandrina, et al.
Publicado: (2021)

Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China
por: Tang, Yi, et al.
Publicado: (2022)

Digoxin, an Overlooked Agonist of RORγ/RORγT
por: Karaś, Kaja, et al.
Publicado: (2019)

SGLT2 inhibitors for patients with heart failure with preserved ejection fraction in China: a cost-effectiveness study
por: Lu, He, et al.
Publicado: (2023)

Digoxin and Amiodarone on the Risk of Ischemic Stroke in Atrial Fibrillation: An Observational Study
por: Lai, Kuan-Cheng, et al.
Publicado: (2018)

Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China
por: Jiang, Yaohui, et al.
Publicado: (2021)

Guideline Adherence of β-blocker Initiating Dose and its Consequence in Hospitalized Patients With Heart Failure With Reduced Ejection Fraction
por: Zhou, Yiling, et al.
Publicado: (2021)

Effects of sacubitril-valsartan on heart failure patients with mid-range ejection fractions: A systematic review and meta-analysis
por: Qin, Jianbin, et al.
Publicado: (2022)

Efficacy and safety of digoxin in acute heart failure triggered by tachyarrhythmia
por: Shrestha, Samyut, et al.
Publicado: (2022)

Association between dosing of spironolactone and outcomes in heart failure with preserved ejection fraction patients combined with chronic kidney disease------Balance of efficacy and risk
por: Li, Jun-Feng, et al.
Publicado: (2023)

Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction
por: López‐Vilella, Raquel, et al.
Publicado: (2021)

Digoxin Enhances the Anticancer Effect on Non-Small Cell Lung Cancer While Reducing the Cardiotoxicity of Adriamycin
por: Wang, Yingying, et al.
Publicado: (2020)

Heart Failure With Midrange Ejection Fraction: Prior Left Ventricular Ejection Fraction and Prognosis
por: Zhang, Xinxin, et al.
Publicado: (2021)

Cost-effectiveness of adding empagliflozin to the standard of care for patients with heart failure with reduced ejection fraction from the perspective of healthcare system in Malaysia
por: Ong, Siew Chin, et al.
Publicado: (2023)

Short-term anti-remodeling effects of gliflozins in diabetic patients with heart failure and reduced ejection fraction: an explainable artificial intelligence approach
por: Mele, Marco, et al.
Publicado: (2023)

Observational cohort study of the safety of digoxin use in women with heart failure
por: Flory, James H, et al.
Publicado: (2012)

Risk Prediction Models and Novel Prognostic Factors for Heart Failure with Preserved Ejection Fraction: A Systematic and Comprehensive Review
por: Lin, Shanshan, et al.
Publicado: (2023)

Comparison of Pharmacological Treatment Effects on Long-Time Outcomes in Heart Failure With Preserved Ejection Fraction: A Network Meta-analysis of Randomized Controlled Trials
por: Lin, Yaowang, et al.
Publicado: (2021)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Determinants of ejection fraction improvement in heart failure patients with reduced ejection fraction
por: Liu, Dan, et al.
Publicado: (2023)

A Narrative Review on the Efficacy and Safety of Loop Diuretics in Patients With Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction
por: Pius, Ruth, et al.
Publicado: (2023)

Safety and Tolerability of Nicotinamide Riboside in Heart Failure With Reduced Ejection Fraction
por: Wang, Dennis D., et al.
Publicado: (2022)

The effect of digoxin on renal function in patients with heart failure
por: Shah, Parin, et al.
Publicado: (2021)

A phase I study of the safety, tolerability, and pharmacokinetics of contezolid acefosamil after intravenous and oral administration in healthy Chinese subjects
por: Yang, Haijing, et al.
Publicado: (2023)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

The Safety and Effectiveness of Intravenous Contrast-Enhanced Sonography in Chinese Children—A Single Center and Prospective Study in China
por: Mao, Muyi, et al.
Publicado: (2019)

Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: A meta-analysis of randomized clinical trials
por: Xiang, Yajie, et al.
Publicado: (2019)

Association Between Digoxin Use and Cancer Incidence: A Propensity Score-Matched Cohort Study With Competing Risk Analysis
por: Tai, Chi-Jung, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9q2ekdsuvce73jca6jos269r6c